Skip to main content
OpenTrials
Completed

NCT Number: NCT00802906

Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

The purpose of this study is to evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells, whereas the intravitreal injection should non-selectively stop the RPE leakage.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Central Serous Chorioretinopathy Eye Diseases Retinal Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ZAU Department of VR surgery

Frankfurt am Main, Hesse, 60590, Germany

About this study

To evaluate the clinical efficacy of an initial subthreshold retinal micropulselasercoagulation in twelve eyey per group versus a single intravitreal 1.5mg bevacizumab injection in central serous choriretinopathy, as the micropulse will selectively treat the damaged RPE to induce reproliferation of healthy RPE cells. BCVA in EDTRS score, OCT, and leakage in FLA, static perimetry of both groups will be correlated to a control group without treatment over 10 months.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CSC of >4 months duration

Exclusion criteria

  • History of macular or chorioretinal inflammation
  • Lens / corneal opacities

Treatment and study plan

subthreshold micropulselaser

Device

on demand if leakage is persistent or recurs after initial treatment

Bevacizumab

Drug

1.5 mg initial intravitreal injection

Primary outcomes

  1. BCVA in EDTRS values

    Time frame: 24 months

Secondary outcomes

  1. OCT, leakage in FA, defects in satic perimetry

    Time frame: 24 months

Sponsors and collaborators

Lead sponsor

Johann Wolfgang Goethe University Hospital

Other

Registry information

Official study title

Prospective Study on the Efficacy of 1.5mg Bevacizumab Versus Selective Subthreshold Micropulslaser in Central Serous Chorioretinopathy

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Dec 5, 2008
Registry last updated
Sep 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.